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Background: The relationship between osteocalcin and atherosclerosis remains unclear. This might be due to different
degrees of confounding from factors that are associated with serum osteocalcin level, such as metabolic-related
variables. This study aimed to investigate the relationship between serum osteocalcin level and carotid intima-media
thickness (C-IMT) in a metabolically healthy population.
Methods: A total of 476 subjects with normal values for weight, glucose tolerance, blood pressure, and lipids
(age range, 20–75 years; 155 men, 201 premenopausal women, 120 postmenopausal women) from the Shanghai
Obesity Study were recruited for this cross-sectional study. Subjects with a history of cardiovascular disease or
carotid plaque were excluded. C-IMT was measured by ultrasonography. Serum osteocalcin level was assessed by
an electrochemiluminescence immunoassay.
Results: Median C-IMT in the entire study population was 0.55 mm with an interquartile range of 0.50–0.60 mm.
C-IMT in premenopausal women was significantly lower than that in men and postmenopausal women (all P < 0.001).
The median (interquartile range) of serum osteocalcin level in the entire population was 17.02 (13.31–21.47) ng/mL.
Serum osteocalcin level in postmenopausal women was significantly higher than that in men and premenopausal
women (all P < 0.001), while the level of serum osteocalcin in men was also significantly higher than that in
premenopausal women (P < 0.001). No significant correlation was found between C-IMT and serum osteocalcin
level in either men or postmenopausal women. There was a significant, inverse correlations between C-IMT and
serum osteocalcin level in premenopausal women after adjustment of age, but this association was eliminated
after adjustment for other confounding factors.
Conclusions: Serum osteocalcin level was not independently associated with C-IMT in a metabolically healthy
Chinese population.
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Osteocalcin is a synthetic osteoblast-specific protein which
is involved in the regulation of bone, glucolipid metabolism
and in maintaining homeostasis [1–6]. Recent studies have
investigated whether osteocalcin is associated with sub-
clinical and clinical atherosclerotic coronary artery disease* Correspondence: byq522@163.com
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creativecommons.org/publicdomain/zero/1.0/(CAD), but these studies have yielded inconsistent results.
In some cases, studies have found inverse associations be-
tween osteocalcin and CAD [7–12]. For example, several
studies have shown that subjects with CAD had signifi-
cantly lower serum osteocalcin level than those without
CAD [8, 9]. Similarly, serum osteocalcin level in subjects
with type 2 diabetes mellitus (T2DM) has been found
to be inversely correlated with subclinical measures of
CAD, such as carotid intima-media thickness (C-IMT) and
plaque score, independent of confounding factors [10–12].
In contrast to studies reporting an inverse association,
some studies have reported no association or a positivele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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of CAD. For example, population-based longitudinal study
by Holvik et al. found that there was no association be-
tween plasma osteocalcin level and cardiovascular diseases
(CVD) in younger-old subjects (65–74 years), but a higher
plasma osteocalcin concentration was associated with a
reduced risk of CVD in older-old men (≥75 years) while
with an increased risk of CVD in older-old women
(≥75 years) [13]. However, other research by Reyes-Garcia
et al. observed that subjects with CAD had significantly
higher serum osteocalcin level than those without CAD,
and that serum osteocalcin level in women was positively
correlated with C-IMT [14].
It is unclear why the studies noted above have reported
contradictory findings on the association between serum
osteocalcin level and atherosclerosis. The lack of consistency
might be due to different study populations, or different de-
grees of confounding from factors that are associated with
serum osteocalcin level, such as metabolic-related variables.
In any event, the inconsistent results suggest that additional
research into the association between osteocalcin and ath-
erosclerosis is warranted, particularly in metabolically health
populations that could help limit confounding from meta-
bolic factors. Accordingly, the present study investigated the
association between serum osteocalcin level and subclinical




Subjects were recruited from the Shanghai Obesity Study
(SHOS) between December 2009 and December 2011.
The detailed rules for implementation of the SHOS have
been described in previous study [15]. Subjects were
included if they met the following criteria for being
normal-weight, metabolically healthy individuals: (i)
body mass index (BMI) between at least 18.5 and less
than 25.0 kg/m2 [16]; (ii) normal glucose tolerance, de-
fined as a fasting plasma glucose (FPG) level less than
6.1 mmol/L and 2-h plasma glucose (2hPG) level less
than 7.8 mmol/L [17]; (iii) normotensive, defined as
systolic blood pressure (SBP) less than 130 mmHg and
a diastolic blood pressure (DBP) less than 85 mmHg
[18]; (iv) normal lipid status, defined as serum total
cholesterol (TC) less than 5.18 mmol/L, serum triglyc-
erides (TG) less than 1.70 mmol/L, serum high-density
lipoprotein cholesterol (HDL-C) level of 1.04 mmol/L
or higher, and serum low-density lipoprotein cholesterol
(LDL-C) less than 3.37 mmol/L [19]. Subjects were ex-
cluded if they had a known history of CVD or carotid
plaque, or had any infections, hepatic or renal dysfunction,
malignant tumors, or were taking medicine that may in-
fluence the level of serum osteocalcin. After applying the
inclusion and exclusion criteria noted above, a total of 476subjects were available for study. The study was approved
by the Ethics Committee of Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital, and was conducted in
accordance with the Declaration of Helsinki. Data must be
handled so as to not compromise study participants’ priv-
acy. All participants provided written informed consent
prior to enrollment.
Questionnaire data
Each subject answered a standard questionnaire. The ques-
tionnaire assessed history of medical conditions, family
history of disease, current medications use, and smoking
history and other lifestyle factors. Subjects who smoked
at least one cigarette per day for over half a year were
defined as current smokers [15].
Anthropometric and laboratory measurements
Height was measured with a stadiometer after the subject
had removed his or her shoes and hats. Subjects were re-
quired to keep their eye-sight horizontal, with the back of
the head, shoulder blades, buttocks, calves, and heels all
touching the stadiometer’s vertical board, and their height
was then recorded to the nearest 0.1 cm. Body weight
was measured by a calibrated bathroom scale. Subjects
removed their shoes and outer clothing and stood still
in the middle of the scale, with feet slightly apart, until
the scale’s weight reading had stabilized. Subjects’ weight
was then recorded to the nearest 0.1 kg. BMI was calcu-
lated as body weight in kilo-grams divided by height in
meters squared. Waist circumference (W) was measured
at the horizontal plane between the inferior costal margin
and the iliac crest on the mid-axillary line. Blood pressure
was measured 3 times with a mercury sphygmomanom-
eter at 3-min intervals, after the subject had been at
rest for at lest 10 min. Form these three blood pressure
measurements, a mean value was calculated. The techniques
for laboratory measurement of blood samples have
been described previously [15]. Serum total osteocalcin
level was measured using an electrochemiluminescence
immunoassay (Roche Diagnostics GmbH, Mannheim,
Germany), and the intra-assay and inter-assay coefficients
of variation for osteocalcin were 1.2 to 4.0 % and 1.7 to
6.5 %, respectively [15].
Ultrasonographic measurement of C-IMT
An experienced radiologist, who was blinded to study re-
sults, made ultrasound measurements of C-IMT with a
high-resolution B-mode scanner (Voluson 730 Expert; GE
Healthcare, Waukesha, WI, USA). A 10-MHz probe was
utilized, and C-IMT was measured on both sides of the
common carotid artery approximately 1.0 cm proximal
to the carotid bulb. The average C-IMT value of the two
sides was used for analysis [20].
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Variables with normal distributions were described in terms
of the mean ± standard deviation, while variables with
skewed distribution were described in terms of the median
and 25th and 75th percentiles. The independent-sample stu-
dent’s t-test (for normally distributed variables) and the Wil-
coxon rank-sum test (for skewed variables) were used to
assess differences in characteristics between gender groups.
Categorical variables were summarized using frequencies
and percent, and differences in categorical variables among
groups were assessed by the chi-square test. Partial correla-
tions were calculated to analyze C-IMT’s association with
serum osteocalcin and other clinical variables after adjust-
ment for age. Multivariable linear regression models were
run to examine the relationship between C-IMT (dependent
variable) and serum osteocalcin level (independent variable)
after adjustment for other variables. Statistical Product and
Service Solutions software (SPSS for Windows, Version
16.0. Chicago, IL: SPSS Inc.) was used to perform statistical
analyses. All statistical tests were two tailed, and p-values
less than 0.05 were considered statistically significant.
Results
Clinical characteristics of study subjects
The 476 subjects enrolled in the present study had an
age range of 20 to 75 years (mean 47.9 ± 9.5 years).Table 1 Clinical characteristics of study subjects
Variables Men
n 155
Age (years) 50.1 ± 10.6
BMI (kg/m2) 22.0 ± 1.8
W (cm) 78.0 (74.0–84.0)
SBP (mmHg) 119.3 (110.0–121.3)
DBP (mmHg) 74.7 (70.0–79.3)
FPG (mmol/L) 5.1 ± 0.4
2hPG (mmol/L) 5.5 ± 1.1
HbA1c (%) 5.4 (5.2–5.6)
FINS (mU/L) 5.5 (3.8–7.5)
HOMA-IR 1.2 (0.8–1.7)
TC (mmol/L) 4.34 ± 0.48
TG (mmol/L) 0.88 (0.69–1.17)
HDL-C (mmol/L) 1.40 (1.25–1.61)
LDL-C (mmol/L) 2.65 ± 0.48
CRP (mg/L) 0.5 (0.3–0.8)
Smoking, n (%) 76 (49.0)
CVD family history, n (%) 45 (29.0)
Data were presented as mean ± standard deviation or median (interquartile range)
BMI body mass index, W waist circumference, SBP systolic blood pressure, DBP diast
HbA1c glycated hemoglobin, FINS fasting insulin, HOMA-IR homoeostasis model ass
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, CRP
*P < 0.05; **P < 0.01 vs. men; ***P < 0.05; ****P < 0.01 vs. premenopausal womenSubjects were gender-stratified into 155 men, 201 pre-
menopausal women, and 120 postmenopausal women.
The years since menopause of postmenopausal women
was 5.6 ± 4.6 years. The clinical characteristics of study
subjects have been described in Table 1. Men had a sig-
nificantly higher SBP, DBP level, and a higher frequency
of smoking than either premenopausal or postmeno-
pausal women (all P < 0.05). Postmenopausal women had
higher levels of W, 2hPG, glycated hemoglobin (HbA1c),
TC, TG, LDL-C, and C-reactive protein (CRP) than pre-
menopausal women (all P < 0.05).
Comparison of C-IMT and serum osteocalcin level accord-
ing to gender categorizes
The median C-IMT for the total study population was
0.55 mm with an interquartile range of 0.50–0.60 mm.
The C-IMT of premenopausal women was significantly
lower than that of men [0.50 (0.50–0.60) mm vs. 0.60
(0.50–0.65) mm, P < 0.001] and postmenopausal women
[0.50 (0.50–0.60) mm vs. 0.60 (0.55–0.60) mm, P < 0.001].
However, the difference in C-IMT between men and post-
menopausal women was not statistically significant [0.60
(0.50–0.65) mm vs. 0.60 (0.55–0.60) mm, P > 0.05].
The overall median (interquartile range) serum osteo-
calcin level was 17.02 (13.31–21.47) ng/mL, with a level
of 18.48 (15.53–21.74) ng/mL in men, 14.36 (11.88–Premenopausal women Postmenopausal women
201 120
42.0 ± 6.8** 55.0 ± 4.4**,****
21.5 ± 1.7* 21.7 ± 1.8
72.0 (69.5–77.0)** 75.0 (71.0–80.0)**,****
110.7 (103.3–120.0)** 112.7 (107.7–120.0)*
72.0 (66.7–79.2)* 71.7 (69.3–78.7)*
5.1 ± 0.4 5.1 ± 0.4
5.7 ± 1.0 6.0 ± 1.0**,****
5.4 (5.1–5.6) 5.5 (5.3–5.8)**,****
6.4 (4.9–8.8)** 6.1 (4.5–7.6)
1.4 (1.1–2.0)** 1.4 (1.0–1.7)
4.28 ± 0.54 4.54 ± 0.43**,****
0.79 (0.61–1.00)** 0.87 (0.65–1.16)***
1.53 (1.37–1.78)** 1.62 (1.45–1.79)**
2.50 ± 0.46** 2.61 ± 0.44***
0.3 (0.2–0.7)** 0.5 (0.2–0.8)****
6 (3.0)** 1 (0.8)**
52 (25.9) 47 (39.2)***
olic blood pressure, FPG fasting plasma glucose, 2hPG 2-h plasma glucose,
essment-insulin resistance index, TC total cholesterol, TG triglyceride, HDL-C
C-reactive protein, CVD cardiovascular disease
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(18.15–26.90) ng/mL in postmenopausal women. Serum
osteocalcin level in postmenopausal women was signifi-
cantly higher than in men and premenopausal women
(all P < 0.001), while serum osteocalcin level in men was
also significantly higher than in premenopausal women
(P < 0.001) (Fig. 1).
Association of C-IMT with other anthropometric and bio-
chemical parameters
As shown in Table 2, the correlation between C-IMT
and serum osteocalcin level was not significant in men
or postmenopausal women after adjustment of age (all
P > 0.05). However, in premenopausal women, C-IMT
showed a significant, inverse correlation with serum osteo-
calcin level (r = −0.145, P = 0.041). Therefore, a stepwise
multivariable regression model was run only in premeno-
pausal women to determine if serum osteocalcin level was
associated with C-IMT in these subjects, independent of
other confounding factors. C-IMT was the dependent
variable, and the parameters significantly correlated with
C-IMT were set as independent variables, including age,
BMI, W, SBP, DBP, FPG, serum fasting insulin (FINS),
CRP, smoking status, and CVD family history, and osteo-
calcin. The model indicated that age, SBP, FPG, FINS and
CRP were independently associated with C-IMT (all P <
0.05, Table 3), but that serum osteocalcin level was not
independently associated with C-IMT in premenopausal
women (P >0.05).
Discussion
Evidences indicate that skeleton works not only as a
structural scaffold but also as an endocrine organ. Many
bioactive factors secreted from bone, such as osteocalcin
and osteoprotegerin, have a regulatory role in energy
metabolism [21, 22]. Recent studies have suggested aFig. 1 Serum osteocalcin level in subjects with different gender
categorizes. Data were shown as median with 25th and 75th
percentiles. *P < 0.001 compared with men, #P < 0.001 compared
with premenopausal womenpotentially important role for osteocalcin in regulating
the function of vascular endothelial cells, and the car-
diovascular system [23, 24]. This suggests osteocalcin
could be involved in the development of CAD. Several
studies have investigated the association between osteocal-
cin and atherosclerosis, but results have not been con-
sistent. Some studies suggest osteocalcin may actually
be protective against early atherosclerosis. For example,
a study from Korea demonstrated an independent effect
of osteocalcin on vascular endothelial cells, suggesting
that osteocalcin could have beneficial effects on athero-
sclerosis [25]. Our previous study in high fat diet animals
indicate that osteocalcin has an endothelial-protective ef-
fect in atherosclerosis through mediating the PI3K/Akt/
eNOS signaling pathway, and exogenous osteocalcin can
improve the function of human umbilical vein endothelial
cells in vitro [26]. Consistent with this result, a study in
1319 postmenopausal women found serum osteocalcin
level was independently and inversely correlated with
C-IMT [27].
The arteries plaques and aortic calcifications would
emerge in the development and progression of athero-
sclerosis. Moreover, coronary atherosclerosis is the
major adverse cardiac events of atherosclerosis. Likewise,
a study from Japan of 50 patients with T2DM found that
changes in the serum osteocalcin level were significantly
and inversely correlated with plaque score [12]. Another
study of 774 elderly men found that higher osteocalcin
level was associated with lower abdominal aortic calcifi-
cation progression [28]. Additionally, our group and others
have found inverse associations between serum osteocalcin
level and coronary atherosclerosis in Chinese men [8, 9].
However, in contrast to the studies above, some data
indicate that osteocalcin shows no association, or even
shows a positive association, with atherosclerosis or CVD.
Thus, a follow-up study of 1290 Korean men found that
the serum osteocalcin level was not associated with the
development of CVD, even after adjustment for other risk
factors for CVD [29]. Another 4.1-year follow-up study
also reported no association between plasma osteocalcin
level and CVD in younger-old subjects (65–74 years) [13].
A positive correlation between serum osteocalcin level
and atherosclerosis was found in a study of 78 patients
with T2DM. In particular, the level of osteocalcin in sub-
jects with CAD was higher than in those without CAD,
and higher concentrations of osteocalcin were found in
women with abnormal IMT, carotid plaques, and aortic
calcifications compared to normal women [14].
It is unclear why the results noted above have been so
inconsistent. One possible explanation is that the studies
were conducted in different populations and ethnic groups.
Another explanation may be that different studies were
affected to different degrees by confounding from
metabolic factors. Studies have demonstrated there is a
Table 2 Correlations of C-IMT with various clinical and biochemical parameters after adjustment for age
Variables Men Premenopausal women Postmenopausal women
r P r P r P
BMI 0.067 0.410 0.162 0.022 −0.027 0.768
W 0.140 0.083 0.153 0.030 −0.002 0.982
SBP 0.269 0.001 0.205 0.004 0.194 0.035
DBP 0.140 0.083 0.168 0.017 0.108 0.243
FPG 0.101 0.212 0.232 0.001 0.024 0.793
2hPG −0.090 0.264 −0.046 0.519 −0.020 0.827
HbA1c −0.137 0.091 −0.054 0.447 0.099 0.286
FINS 0.267 0.001 0.262 <0.001 0.103 0.267
HOMA-IR 0.269 0.001 0.283 <0.001 0.103 0.264
TC −0.141 0.081 −0.034 0.630 −0.060 0.518
TG 0.137 0.090 0.087 0.220 −0.003 0.974
HDL-C −0.219 0.006 −0.046 0.518 0.035 0.709
LDL-C 0.113 0.161 0.089 0.209 0.062 0.502
CRP 0.011 0.889 0.208 0.003 0.141 0.126
Osteocalcin 0.034 0.674 −0.145 0.041 −0.156 0.090
C-IMT carotid intima-media thickness, BMI body mass index, W waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma
glucose, 2hPG 2-h plasma glucose, HbA1c glycated hemoglobin, FINS fasting insulin, HOMA-IR homoeostasis model assessment-insulin resistance index, TC total
cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, CRP C-reactive protein
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glucolipid metabolic disorders, obesity, and metabolic
syndrome. Each of these metabolic dysfunctions are re-
lated to the progression of atherosclerosis, and therefore,
are considered as risk factors for CVD [30]. Researches in-
dicate that subjects with diabetes or impaired glucose
tolerance have significantly lower serum osteocalcin level
than the subjects with normal glucose tolerance [31, 32],
and that serum osteocalcin level of subjects with meta-
bolic syndrome are lower than in those without metabolic
syndrome [33]. These findings suggest that the association
of osteocalcin with atherosclerosis may be influenced
by metabolic variables. Thus, to eliminate potential con-
founding from metabolic variables, it might be useful toTable 3 Association of C-IMT with other anthropometric and
biochemical parameters in premenopausal women
Independent variables Standardized β t P
Age 0.300 4.605 <0.001
SBP 0.135 1.986 0.048
FPG 0.150 2.345 0.020
FINS 0.176 2.684 0.008
CRP 0.209 3.423 0.001
Independent variables included in premenopausal women were as follows:
age, BMI, W, SBP, DBP, FPG, FINS, CRP, smoking status, CVD family history, and
osteocalcin. Only the statistical significant parameters correlated with C-IMT
were presented in Table 3 after stepwise regression analysis
C-IMT carotid intima-media thickness, BMI body mass index, W waist circumference,
SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma
glucose, FINS fasting insulin, CRP C-reactive protein, CVD cardiovascular diseaseexplore the relationship between serum osteocalcin level
and atherosclerosis in metabolically healthy persons. In
this regard, a study of 638 men with normal glucose toler-
ance by Ma et al. showed an inverse association between
serum osteocalcin level and the prevalence of carotid
plaque. However, the study did not account for the influ-
ence of other metabolic factors, such as obesity, hyper-
tension and dyslipidemia [31]. Therefore, to better clarify
the relationship of serum osteocalcin level to atheroscler-
osis without confounding from metabolic variables, the
present study excluded subjects with traditional risk
factors for CVD (overweight, obesity, hyperglycemia, hyper-
tension, and dyslipidemia), and further eliminated those
with history of CVD or carotid plaque. In accordance with
the previous findings of gender-related difference in serum
osteocalcin concentration [32], the serum osteocalcin level
of postmenopausal women was significantly higher than
those of men and premenopausal women in this study.
There was no statistically significant correlation between
serum osteocalcin level and C-IMT in either men or post-
menopausal women. Although an simple correlation
between these two factors was found in premenopausal
women, a multivariable model failed to demonstrate a
significant association between serum osteocalcin level
and C-IMT after adjusting for relevant confounding factors.
Our previous study involving animal models also found
that exogenous osteocalcin was not related to endothelium-
dependent relaxation in mice fed with chow diet, which is
in agreement with the present study’s finding of metabolic-
ally healthy human to some extent [26].
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Because of the cross-sectional nature of this study, we
were not able to clarify whether the association between
osteocalcin and C-IMT was causal. Thus, additional pro-
spective studies are needed to assess this association. In
addition, serum total osteocalcin is composed of uncarboxy-
lated and carboxylated forms. Initial animal and in vitro
studies indicated that undercarboxylated osteocalcin is
the biologically active isoform mediating the metabolic
functions. However, several recent clinical studies have
demonstrated that not only undercarboxylated but also
total osteocalcin were associated with energy metabolism
and atherosclerosis as well [8, 9, 14]. Because lack of an
automated assay to examine the uncarboxylated form, our
study only measured serum total osteocalcin.
Conclusions
This study is the first to report that serum osteocalcin
level is not independently correlated with C-IMT in a
metabolically healthy population.
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